IBDEI1AI ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22850,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22850,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,22850,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,22850,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,22851,0)
 ;;=204.12^^125^1397^17
 ;;^UTILITY(U,$J,358.3,22851,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22851,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,22851,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,22851,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,22852,0)
 ;;=204.20^^125^1397^114
 ;;^UTILITY(U,$J,358.3,22852,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22852,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,22852,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,22852,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,22853,0)
 ;;=204.21^^125^1397^116
 ;;^UTILITY(U,$J,358.3,22853,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22853,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,22853,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,22853,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,22854,0)
 ;;=204.22^^125^1397^115
 ;;^UTILITY(U,$J,358.3,22854,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22854,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,22854,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,22854,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,22855,0)
 ;;=205.02^^125^1397^5
 ;;^UTILITY(U,$J,358.3,22855,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22855,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,22855,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,22855,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,22856,0)
 ;;=205.12^^125^1397^20
 ;;^UTILITY(U,$J,358.3,22856,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22856,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,22856,1,5,0)
 ;;=5^CML,In Relapse
 ;;^UTILITY(U,$J,358.3,22856,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,22857,0)
 ;;=284.81^^125^1397^14
 ;;^UTILITY(U,$J,358.3,22857,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22857,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,22857,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,22857,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,22858,0)
 ;;=284.89^^125^1397^13
 ;;^UTILITY(U,$J,358.3,22858,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22858,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,22858,1,5,0)
 ;;=5^Aplastic Anemia d/t Chronic Disease
 ;;^UTILITY(U,$J,358.3,22858,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,22859,0)
 ;;=289.84^^125^1397^119
 ;;^UTILITY(U,$J,358.3,22859,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22859,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,22859,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,22859,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,22860,0)
 ;;=V10.91^^125^1397^67
 ;;^UTILITY(U,$J,358.3,22860,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22860,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,22860,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,22860,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,22861,0)
 ;;=V10.91^^125^1397^66
 ;;^UTILITY(U,$J,358.3,22861,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22861,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,22861,1,5,0)
 ;;=5^H/O Malignant Neoplasm,Unspec
 ;;^UTILITY(U,$J,358.3,22861,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,22862,0)
 ;;=465.9^^125^1398^70
 ;;^UTILITY(U,$J,358.3,22862,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22862,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,22862,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,22862,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,22863,0)
 ;;=462.^^125^1398^61
 ;;^UTILITY(U,$J,358.3,22863,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22863,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,22863,1,5,0)
 ;;=5^Sore Throat
 ;;
 ;;$END ROU IBDEI1AI
